MiNK Therapeutics, Inc. (INKT): who owns it and who trades it
As of Oct 30, 2026, INKT insiders reported 9 open-market sales worth $120K and no purchases in the last 12 months, with 0% of the sale value made under pre-set 10b5-1 plans. The largest seller was Jennifer Buell (CEO), with $73.3K.
Latest filing Oct 30, 2026. From Form 4, 13F and Schedule 13D/G filings.
At a glance
Insider trades
In the last 12 months, INKT insiders reported $0 of open-market purchases and $120K of sales. 0% of the sale value was under a 10b5-1 plan, a schedule set up in advance.
Purchases and sales by month
Latest trades
| Date | Insider | Role | Type | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|---|
| Oct 12, 2026 | Jennifer Buell | CEO | Sale | 6,938 | $10.56 | $73.3K | Form 4 |
| Jun 4, 2026 | Barbara Ryan | Director | Sale | 1,000 | $12.80 | $12.8K | Form 4 |
| Jun 4, 2026 | Barbara Ryan | Director | Sale | 500 | $12.68 | $6.3K | Form 4 |
| Mar 10, 2026 | Barbara Ryan | Director | Sale | 500 | $15.30 | $7.7K | Form 4 |
| Mar 10, 2026 | Barbara Ryan | Director | Sale | 500 | $15.57 | $7.8K | Form 4 |
| Mar 10, 2026 | Barbara Ryan | Director | Sale | 300 | $15.28 | $4.6K | Form 4 |
| Mar 9, 2026 | Barbara Ryan | Director | Sale | 200 | $10.17 | $2K | Form 4 |
| Mar 2, 2026 | Barbara Ryan | Director | Sale | 100 | $10.83 | $1.1K | Form 4 |
| Feb 27, 2026 | Barbara Ryan | Director | Sale | 400 | $10.86 | $4.3K | Form 4 |
Insiders by value traded
| Insider | Role | Bought | Sold | Last trade |
|---|---|---|---|---|
| Jennifer Buell | Chief Executive Officer, Director | – | $73.3K | Oct 12, 2026 |
| Barbara Ryan | Director | – | $46.6K | Jun 4, 2026 |
What this data shows, and what it doesn't
- Shows: open-market purchases and sales by officers, directors and 10%+ owners, reported on Form 4 within two business days of the trade.
- Leaves out: stock awards, option exercises, shares withheld for tax and gifts. These are not trades at a market price chosen by the insider.
- "plan" marks a sale made under a Rule 10b5-1 plan, a schedule set up in advance.
- Fund holders come from 13F reports, a snapshot at quarter end filed up to 45 days later.
- Filings are self-reported and can be amended. Each trade links to its original filing. Methodology
INKT short interest
Low short interest. 1.1% of INKT shares are sold short: about 1 share in 93. Over the last 12 reports the number of shares short went down 55%.
As a rough guide, under 5% is low, 5–10% is moderate, 10–20% is high and over 20% is very high.
As of Oct 30, 2026, 55,094 INKT shares were sold short, 1.1% of the shares outstanding, up 15.3% from the report before. At the average daily volume of 12,851 shares, buying them all back would take about 4.3 trading days (days to cover).
Shares short, % of all shares
Days to cover
Every report
| Settlement date | Shares short | % of shares | Change | Avg daily volume | Days to cover |
|---|---|---|---|---|---|
| Oct 30, 2026 | 55,094 | 1.08% | +15% | 12,851 | 4.3 |
| Oct 15, 2026 | 47,778 | 0.94% | -4% | 19,974 | 2.4 |
| Sep 30, 2026 | 49,583 | 0.97% | -13% | 15,898 | 3.1 |
| Sep 15, 2026 | 57,136 | 1.12% | -12% | 18,421 | 3.1 |
| Aug 31, 2026 | 64,965 | 1.27% | -17% | 9,506 | 6.8 |
| Aug 14, 2026 | 78,320 | 1.53% | -17% | 8,666 | 9.0 |
| Jul 31, 2026 | 94,092 | 1.89% | -6% | 10,044 | 9.4 |
| Jul 15, 2026 | 99,574 | 2.01% | -11% | 14,625 | 6.8 |
| Jun 30, 2026 | 112,459 | 2.26% | -3% | 18,586 | 6.0 |
| Jun 15, 2026 | 115,835 | 2.33% | -1% | 42,432 | 2.7 |
| May 29, 2026 | 116,445 | 2.34% | -5% | 53,104 | 2.2 |
| May 15, 2026 | 122,957 | 2.48% | +27% | 27,682 | 4.4 |
Short sellers borrow shares and sell them, hoping to buy them back for less. A high number means many such bets are open. It does not say where the price will go. Source: FINRA equity short interest, reported by brokers twice a month (positions on the 15th and the last business day) and published about 7 business days later. % of shares uses the share count on the company's latest SEC filing. What short interest means · Most shorted stocks
MiNK Therapeutics company events
MiNK Therapeutics filed 8 reports on Form 8-K in the last 12 months, 2 of them about an important change (leadership). The latest was on Aug 13, 2026.
- Aug 13, 2026ResultsReleased financial results. Filing
- Jun 23, 2026VoteReported shareholder vote results. Filing
- May 15, 2026ResultsReleased financial results. Filing
- Mar 31, 2026ResultsReleased financial results. Filing
- Mar 27, 2026AnnouncementIn response to recent investor inquiries regarding third-party postings concerning potential combination trials involving agenT-797, MiNK Therapeutics, Inc. is providing the following clarification: The Company is actively engaged in discussions with multiple parties regarding potential combination… Filing
- Mar 19, 2026LeadershipMiNK Therapeutics Inc.'s Board of Directors appointed Melissa Orilall, Agenus Inc.'s current Vice President, Global Financial Operations to serve as the Company's Principal Financial Officer. Filing
- Jan 2, 2026LeadershipRobert Kadlec, MD, resigned from the Board of Directors of MiNK Therapeutics, Inc., including all committees thereof, effective December 29, 2025, in connection with his acceptance of a senior public service role within the United States government as Assistant Secretary of War for Nuclear… Filing
- Dec 8, 2025ResultsReleased financial results. Filing
From 8-K reports, which a company must file within 4 business days of an important event. Where a report is about a change such as a new CEO, the sentence is the first one from the report itself, shortened. Each row links to the original filing. Company events this week
MiNK Therapeutics financials
Questions about MiNK Therapeutics, Inc. (INKT) stock
Are INKT insiders buying or selling?
In the last 12 months, INKT insiders reported no open-market purchases and 9 sales worth $120K. The latest trade was on Oct 12, 2026. See every trade.
What is the short interest in INKT?
As of Oct 30, 2026, 55,094 INKT shares were sold short, 1.1% of the shares outstanding, up 15.3% from the report before. At the average daily volume of 12,851 shares, buying them all back would take about 4.3 trading days (days to cover). See the history.
Source: SEC Form 4 (insiders, filed within 2 business days), 13F (funds, up to 45 days after quarter end) and Schedule 13D/13G filings. Only open-market purchases (code P) and sales (code S) are shown. Data only, not investment advice. How we collect it.